<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22958" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lymphocyte Depleted Hodgkin Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thida</surname>
            <given-names>Aye M.</given-names>
          </name>
          <aff>New York Health + Hospitals/Woodhull</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tun</surname>
            <given-names>Aung M.</given-names>
          </name>
          <aff>Division of Hematology, Mayo Clinic, Rochester, MN</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aye Thida declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aung Tun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22958.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lymphocyte-depleted classic Hodgkin lymphoma is the rarest subtype of classic Hodgkin lymphoma, accounting for 1% to 1.5% of classic Hodgkin lymphoma cases in western countries. Most patients with lymphocyte-depleted classic Hodgkin lymphoma experience B symptoms such as unexplained fever more than 100.4 F (38 C), drenching night sweats, and unexplained loss of more than 10% of body weight over 6 months. The 5-year progression-free survival and overall survival rates are significantly lower in these patients than those with other subtypes of classic Hodgkin lymphoma. This activity describes the evaluation and management of lymphocyte-depleted classic Hodgkin lymphoma and reviews the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of lymphocyte-depleted classic Hodgkin lymphoma.</p></list-item><list-item><p>Outline appropriate evaluation of lymphocyte-depleted classic Hodgkin lymphoma and proper referral.</p></list-item><list-item><p>Review the management options available for lymphocyte-depleted classic Hodgkin lymphoma.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to improve outcomes in patients with lymphocyte-depleted classic Hodgkin lymphoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22958&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22958">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22958.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lymphocyte-depleted classic Hodgkin lymphoma is the rarest subtype of classic Hodgkin lymphoma globally,&#x000a0;although it may be more common in developing countries.<xref ref-type="bibr" rid="article-22958.r1">[1]</xref><xref ref-type="bibr" rid="article-22958.r2">[2]</xref><xref ref-type="bibr" rid="article-22958.r3">[3]</xref> The diagnosis of lymphocyte-depleted classic Hodgkin lymphoma could be challenging, and the disease might be misdiagnosed as more aggressive B-cell or T-cell lymphomas.<xref ref-type="bibr" rid="article-22958.r4">[4]</xref>&#x000a0;Patients with&#x000a0;this disease present more often with unfavorable risk factors and have poorer survival rates than those with other subtypes of classic Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r5">[5]</xref><xref ref-type="bibr" rid="article-22958.r6">[6]</xref></p>
      </sec>
      <sec id="article-22958.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although certain viral infections such as Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV) have been associated with this disease, no specific causal link has been identified.<xref ref-type="bibr" rid="article-22958.r6">[6]</xref><xref ref-type="bibr" rid="article-22958.r7">[7]</xref><xref ref-type="bibr" rid="article-22958.r8">[8]</xref></p>
      </sec>
      <sec id="article-22958.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Lymphocyte-depleted classic Hodgkin lymphoma is regarded as the rarest subtype of classic Hodgkin lymphoma, accounting for 1% to 1.5% of classic Hodgkin lymphoma cases in Western countries.<xref ref-type="bibr" rid="article-22958.r5">[5]</xref><xref ref-type="bibr" rid="article-22958.r9">[9]</xref> However, it may be more common in the developing world.<xref ref-type="bibr" rid="article-22958.r3">[3]</xref>&#x000a0;Approximately 40% of cases are diagnosed in patients aged 60 years and older.<xref ref-type="bibr" rid="article-22958.r9">[9]</xref> Younger patients aged 18 to 39 years are also affected by the disease seen in 28% of cases.<xref ref-type="bibr" rid="article-22958.r9">[9]</xref>&#x000a0;It is twice as common in men as in women.<xref ref-type="bibr" rid="article-22958.r6">[6]</xref> At the time of presentation, 64% of patients have an advanced-stage disease (stage III-IV).<xref ref-type="bibr" rid="article-22958.r6">[6]</xref></p>
      </sec>
      <sec id="article-22958.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The etiology of lymphocyte-depleted classic Hodgkin lymphoma has not been established. However, genetic factors and viral infections such as EBV and HIV may play a role in the pathogenesis of this disease.<xref ref-type="bibr" rid="article-22958.r6">[6]</xref><xref ref-type="bibr" rid="article-22958.r7">[7]</xref><xref ref-type="bibr" rid="article-22958.r8">[8]</xref><xref ref-type="bibr" rid="article-22958.r10">[10]</xref></p>
        <p>
<bold>1. Genetic Disorders</bold>
</p>
        <p>Various gene mutations and chromosomal abnormalities in classic Hodgkin lymphoma affect transcription factors, signaling molecules, tumor suppressor genes, and immune regulators. These result in the transformation of germinal center B-cells to characteristic Hodgkin/Reed-Sternberg (HRS) cells.<xref ref-type="bibr" rid="article-22958.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>1.1. <bold>Genetic Abnormality</bold></bold>
</p>
        <p>A genetic amplification or copy number gain of chromosome 9p24.1 leads to overexpression of programmed death-ligand 1 and 2 (PD-L1 and PD-L2).<xref ref-type="bibr" rid="article-22958.r10">[10]</xref> Moreover, amplification of Janus activated kinase 2 (JAK2) locus induces Janus activated kinase - signal transducers and activators of transcription (JAK-STAT) signaling, leading to increased transcription of PD-L1.<xref ref-type="bibr" rid="article-22958.r10">[10]</xref> The signaling between PD-L1 on HRS cells and programmed cell death-1 (PD-1) receptors on T-cells results in T-cell dysfunction, exhaustion, and subsequent apoptosis.<xref ref-type="bibr" rid="article-22958.r12">[12]</xref> The resultant immunosuppressive tumor microenvironment allows HRS cells to evade an effective anti-tumor immune response.<xref ref-type="bibr" rid="article-22958.r13">[13]</xref></p>
        <p>
<bold>1.2. Aberrant Signaling</bold>
</p>
        <p>Constitutive activation of nuclear factor-kappa B (NF-kappaB) in HRS cells is hypothesized to stimulate proliferation, encourage migration, and inhibit apoptosis of malignant cells.<xref ref-type="bibr" rid="article-22958.r14">[14]</xref> Cooperation of NF-kappaB with activator protein 1 complex (AP-1) causes increased expression of cyclin D2, c-met, and chemokine receptor 7 (CCR7), thus promoting HRS cell proliferation.<xref ref-type="bibr" rid="article-22958.r15">[15]</xref> Additionally, loss-of-function mutations of suppressors of cytokine signaling-1 (SOCS-1) are associated with constitutive activation of JAK-STAT signaling and nuclear phospho-STAT5 accumulation.<xref ref-type="bibr" rid="article-22958.r16">[16]</xref>&#x000a0;</p>
        <p>
<bold>2. Viral Infections</bold>
</p>
        <p>
<bold>2.1. Epstein-Barr Virus</bold>
</p>
        <p>EBV infection is present in 60% to 72% of patients with lymphocyte-depleted classic Hodgkin lymphoma, which is relatively more common than other subtypes of classic Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r6">[6]</xref><xref ref-type="bibr" rid="article-22958.r7">[7]</xref> Besides, EBV has been shown to play a significant role in the pathogenesis of this disease. Latent membrane protein 1 (LMP 1) of EBV induces PD-L1 expression on EBV-infected B-cells through several survival pathways such as the JAK-STAT signaling pathway, NF-kappaB,&#x000a0;and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathways.<xref ref-type="bibr" rid="article-22958.r17">[17]</xref><xref ref-type="bibr" rid="article-22958.r18">[18]</xref><xref ref-type="bibr" rid="article-22958.r19">[19]</xref><xref ref-type="bibr" rid="article-22958.r20">[20]</xref>&#x000a0;</p>
        <p>Moreover, LMP 1 acts as a functional homolog of CD40.<xref ref-type="bibr" rid="article-22958.r21">[21]</xref>&#x000a0;CD40 ligand on activated T-cells typically interacts with CD40 on antigen-presenting cells, leading to a T-cell-dependent immune response.<xref ref-type="bibr" rid="article-22958.r22">[22]</xref> However, in EBV infection, LMP 1 imitates helper T-cell function and allows EBV-infected B-cells to undergo activation, proliferation, and differentiation in the absence of T-cells.<xref ref-type="bibr" rid="article-22958.r23">[23]</xref>&#x000a0;</p>
        <p>
<bold>2.2. Human Immunodeficiency Virus</bold>
</p>
        <p>Approximately 15% of patients with lymphocyte-depleted classic Hodgkin lymphoma have HIV infection&#x000a0;that induces chronic B-cell activation via interacting with CD40-ligand-bearing virions, HIV-associated proteins such as gp120, p17, and nef, and altering cytokine production and release.<xref ref-type="bibr" rid="article-22958.r8">[8]</xref><xref ref-type="bibr" rid="article-22958.r24">[24]</xref><xref ref-type="bibr" rid="article-22958.r25">[25]</xref><xref ref-type="bibr" rid="article-22958.r26">[26]</xref>&#x000a0;Failure to recognize and eradicate EBV-infected B-cells, caused by HIV infection with associated immune dysfunction, also contributes to malignant transformation.<xref ref-type="bibr" rid="article-22958.r27">[27]</xref> Moreover, the HIV p17 protein variant induces EBV oncoprotein, which then leads to the uncontrolled proliferation of B-cells&#x000a0;infected with EBV.<xref ref-type="bibr" rid="article-22958.r27">[27]</xref></p>
      </sec>
      <sec id="article-22958.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The lymphocyte-depleted classic Hodgkin lymphoma diagnosis requires a histopathologic finding of characteristic&#x000a0;HRS cells with abundant basophilic cytoplasm and a distinctive bi-nucleate morphology resembling owl's eyes appearance.<xref ref-type="bibr" rid="article-22958.r28">[28]</xref>&#x000a0;Lymphocyte infiltration is minimally seen in this subtype.&#x000a0;The two morphological variants are diffuse fibrosis and reticular variant.&#x000a0;The former has abundant HRS cells in a hypocellular background with disordered fibrosis, abundant histiocytes, and few plasma cells or eosinophils, while the latter has numerous HRS cells frequently associated with anaplastic and pleomorphic features.</p>
      </sec>
      <sec id="article-22958.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients experience B symptoms such as unexplained fever of more than 100.4 &#x000b0;F (38 &#x000b0;C), drenching night sweats, and unexplained loss of more than 10% of body weight over 6 months.<xref ref-type="bibr" rid="article-22958.r5">[5]</xref> They typically present with an extensive symptomatic disease with a predilection for retroperitoneal lymph nodes, abdominal organs including subdiaphragmatic regions, and bone marrow.<xref ref-type="bibr" rid="article-22958.r28">[28]</xref></p>
      </sec>
      <sec id="article-22958.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For a definitive diagnosis of lymphocyte-depleted classic Hodgkin lymphoma, an excisional lymph node biopsy is generally preferred over a core-needle biopsy.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28272688">[29]</ext-link><xref ref-type="bibr" rid="article-22958.r29">[30]</xref> However, a fine-needle aspiration biopsy (FNAB) is inadequate to establish the diagnosis.<xref ref-type="bibr" rid="article-22958.r30">[31]</xref><xref ref-type="bibr" rid="article-22958.r31">[32]</xref>&#x000a0;Immunophenotyping is also required for a definitive diagnosis, and the HRS cells are positive for CD30 in almost all cases.<xref ref-type="bibr" rid="article-22958.r6">[6]</xref><xref ref-type="bibr" rid="article-22958.r7">[7]</xref> The neoplastic cells are also positive for CD15 and PAX5.&#x000a0;A positive CD20 can be detected in 20% of cases.&#x000a0;They are usually negative for CD3, CD45, and CD79a. Up to 60% to 72% of lymphocyte-depleted classic Hodgkin lymphoma cases may be positive in LMP 1 of EBV.</p>
        <p>Proper staging is important to assess the extent of the disease and to guide therapy. Positron emission tomography (PET) and computed tomography (CT) scans are routinely done for staging evaluation in Hodgkin lymphoma, but contrast-enhanced&#x000a0;CT scans can also be used.<xref ref-type="bibr" rid="article-22958.r32">[33]</xref><xref ref-type="bibr" rid="article-22958.r33">[34]</xref>&#x000a0;A bone marrow biopsy is no longer mandatory for the routine staging of Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r34">[35]</xref> The 2014 Lugano classification is described as follows:<xref ref-type="bibr" rid="article-22958.r35">[36]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: A single lymph node, a group of adjacent lymph nodes, or single extranodal lesions without nodal involvement</p>
          </list-item>
          <list-item>
            <p>Stage II: Two or more lymph node groups on the same side of the diaphragm or limited contiguous extranodal involvement</p>
          </list-item>
          <list-item>
            <p>Stage II bulky: Stage II as above with a bulky feature defined as a single nodal mass of 10 centimeters or greater than a third of the transthoracic diameter</p>
          </list-item>
          <list-item>
            <p>Stage III: Nodes on both sides of diaphragm or nodes above diaphragm with spleen involvement</p>
          </list-item>
          <list-item>
            <p>Stage IV: Additional noncontiguous extra lymphatic involvement</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22958.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Clinical outcomes of classic Hodgkin lymphoma have been improving with the advancement of chemotherapy, radiation therapy, and targeted therapies.<xref ref-type="bibr" rid="article-22958.r36">[37]</xref> The therapeutic approach is based on the age of patients, the extent of disease, high-risk features, comorbidities, potential toxicities, and survivorship.</p>
        <p>
<bold>1. Risk Stratification</bold>
</p>
        <p>Patients are generally classified into 3 groups: early-stage favorable (stage I&#x02013;II without unfavorable factors), early-stage unfavorable (stage I&#x02013;II with any of the unfavorable factors), and advanced-stage disease (stage III-IV). The National Comprehensive Cancer Network defines unfavorable factors for early-stage disease as the presence of B symptoms, erythrocyte sedimentation rate &#x02265; 50 millimeters per hour, bulky mediastinal disease (mediastinal mass ratio &#x0003e; 0.33, or adenopathy &#x0003e; 10 centimeters), and &#x0003e; 3 sites of disease.<xref ref-type="bibr" rid="article-22958.r37">[38]</xref><xref ref-type="bibr" rid="article-22958.r38">[39]</xref><xref ref-type="bibr" rid="article-22958.r39">[40]</xref></p>
        <p>The International Prognostic Score (IPS) helps determine the clinical management and predict prognosis for those with advanced-stage disease.<xref ref-type="bibr" rid="article-22958.r40">[41]</xref> It is a seven-factor scoring system, which includes: serum albumin &#x0003c; 4 grams per deciliter, white-cell count &#x02265; 15,000/cubic millimeter, age &#x02265; 45 years, lymphocyte count &#x0003c; 600/cubic millimeter, or &#x0003c; 8% of white-cell count, hemoglobin &#x0003c; 10.5 grams per deciliter, male sex, and stage IV disease. Patients with high-risk scores (IPS &#x02265; 4) were found to have 5-year freedom from progression (FFP) of 65%, while those with low-risk scores (IPS 0 to 3) had a 5-year FFP of 81%.<xref ref-type="bibr" rid="article-22958.r41">[42]</xref></p>
        <p>
<bold>2. Risk-Adapted Initial Therapy</bold>
</p>
        <p>
<bold>2.1. Early-Stage Hodgkin Lymphoma</bold>
</p>
        <p>Two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy followed by 20 Gy of involved-field radiation therapy (IFRT) is generally considered as the standard therapy for early-stage favorable Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r42">[43]</xref> For those with an unfavorable prognosis, ABVD for 4 cycles with a subsequent 30 Gy of IFRT is considered as the standard initial regimen.<xref ref-type="bibr" rid="article-22958.r43">[44]</xref> The total number of chemotherapy cycles and the role of radiation therapy vary in both favorable and unfavorable patient groups depending on the initial response to chemotherapy and the therapeutic plan (chemotherapy alone versus combined modality therapy). Note that the omission of radiation therapy is associated with a slightly higher risk of disease relapse.<xref ref-type="bibr" rid="article-22958.r44">[45]</xref><xref ref-type="bibr" rid="article-22958.r45">[46]</xref> Cautions must be taken when using bleomycin in elderly patients due to a substantial risk of severe pulmonary toxicity.<xref ref-type="bibr" rid="article-22958.r46">[47]</xref></p>
        <p>
<bold>2.2. Advanced-Stage Hodgkin Lymphoma</bold>
</p>
        <p>Six cycles of ABVD is a preferred therapeutic approach for adult patients with advanced-stage Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r47">[48]</xref> Other regimens that may be considered include escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and brentuximab vedotin, an anti-CD30 antibody-drug conjugate, combined with AVD (doxorubicin, vinblastine, and dacarbazine).<xref ref-type="bibr" rid="article-22958.r48">[49]</xref><xref ref-type="bibr" rid="article-22958.r49">[50]</xref></p>
        <p>
<bold>3. Response-Adapted Therapy</bold>
</p>
        <p>After 2 cycles of ABVD, patients typically undergo the first interim response assessment using PET/CT scans.<xref ref-type="bibr" rid="article-22958.r50">[51]</xref> The results are then interpreted using the Deauville criteria that utilize a 5-point scoring system.<xref ref-type="bibr" rid="article-22958.r51">[52]</xref> The scale depends on the visual comparison of fluorodeoxyglucose (FDG) uptake in involved sites to that of mediastinum and liver. The interpretation is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Score 1: no uptake</p>
          </list-item>
          <list-item>
            <p>Score 2: uptake is equal to or below mediastinum</p>
          </list-item>
          <list-item>
            <p>Score 3: uptake is above mediastinum but equal to or below the liver</p>
          </list-item>
          <list-item>
            <p>Score 4: uptake is moderately higher than liver</p>
          </list-item>
          <list-item>
            <p>Score 5: uptake is markedly higher than liver, any new lesions, or both</p>
          </list-item>
          <list-item>
            <p>Score X: new areas of uptake that are unlikely to be related to lymphoma</p>
          </list-item>
        </list>
        <p>Depending on the Deauville score, further management is individualized for each patient.<xref ref-type="bibr" rid="article-22958.r51">[52]</xref> Bleomycin can safely be omitted from ABVD regimen in patients&#x000a0;who achieved a negative interim PET/CT scan.<xref ref-type="bibr" rid="article-22958.r46">[47]</xref><xref ref-type="bibr" rid="article-22958.r52">[53]</xref><xref ref-type="bibr" rid="article-22958.r53">[54]</xref> In contrast, a biopsy is warranted for patients with a positive interim PET/CT scan, particularly Deauville score 5, to confirm a refractory disease or to establish the definitive diagnosis.<xref ref-type="bibr" rid="article-22958.r35">[36]</xref></p>
        <p>
<bold>4. End-of-Treatment Assessment</bold>
</p>
        <p>At the end of treatment, PET/CT scans help establish remission status using the Deauville criteria.<xref ref-type="bibr" rid="article-22958.r35">[36]</xref><xref ref-type="bibr" rid="article-22958.r51">[52]</xref><xref ref-type="bibr" rid="article-22958.r54">[55]</xref>&#x000a0;A score of 1 to 3 represents a complete metabolic remission irrespective of the size of a residual mass. A residual PET-positivity could represent inflammatory changes or persistent disease, and these patients could undergo further evaluation by biopsy, subsequent radiation therapy, or can potentially be observed.<xref ref-type="bibr" rid="article-22958.r55">[56]</xref></p>
        <p>
<bold>5. Relapsed or Refractory Hodgkin Lymphoma</bold>
</p>
        <p>A diagnosis of relapsed or refractory Hodgkin lymphoma must be confirmed histologically by biopsy.<xref ref-type="bibr" rid="article-22958.r35">[36]</xref> Patients with a relapsed or refractory Hodgkin lymphoma are treated with an alternative chemotherapy regimen, such as ICE (ifosfamide, carboplatin, and etoposide).<xref ref-type="bibr" rid="article-22958.r56">[57]</xref><xref ref-type="bibr" rid="article-22958.r57">[58]</xref> High-dose chemotherapy and autologous stem cell rescue (HDT/ASCR) is the standard of care for patients with chemosensitive disease. Risk factors for relapse or progression after transplantation includes primary refractory disease, remission duration of &#x0003c;1 year following frontline therapy, and the presence of extranodal disease at relapse.<xref ref-type="bibr" rid="article-22958.r58">[59]</xref> Consolidative brentuximab vedotin, with a duration of 1 year, is indicated for patients with high-risk features. Additional therapeutic options include brentuximab vedotin, PD-1 monoclonal antibodies such as nivolumab and pembrolizumab, and allogeneic stem cell transplantation.<xref ref-type="bibr" rid="article-22958.r59">[60]</xref><xref ref-type="bibr" rid="article-22958.r60">[61]</xref><xref ref-type="bibr" rid="article-22958.r61">[62]</xref><xref ref-type="bibr" rid="article-22958.r62">[63]</xref><xref ref-type="bibr" rid="article-22958.r63">[64]</xref></p>
      </sec>
      <sec id="article-22958.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Lymphadenopathy can be seen in various conditions such as infection, autoimmune disorders, and malignancies. Patients with lymphadenopathy should undergo proper workups. A definitive diagnosis requires a biopsy with histopathological and immunohistochemical examinations. It is prudent to obtain adequate tissue for histopathologic analysis, particularly for patients with suspected Hodgkin lymphoma, to yield a definitive diagnosis.<xref ref-type="bibr" rid="article-22958.r64">[65]</xref></p>
      </sec>
      <sec id="article-22958.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with lymphocyte-depleted classic Hodgkin lymphoma have more adverse risk factors than those with other subtypes of classic Hodgkin lymphoma. The 5-year progression-free survival and overall survival rates are significantly lower in these patients than those with other subtypes of classic Hodgkin lymphoma.<xref ref-type="bibr" rid="article-22958.r5">[5]</xref></p>
      </sec>
      <sec id="article-22958.s12" sec-type="Complications">
        <title>Complications</title>
        <p>In long-term survivors of Hodgkin lymphoma, the most serious late complications include secondary cancers,&#x000a0;cardiovascular diseases especially in patients treated with mediastinal irradiation and/or anthracycline-based chemotherapy, hypothyroidism related to mediastinal irradiation,&#x000a0;and infertility particularly associated with BEACOPP regimen.<xref ref-type="bibr" rid="article-22958.r65">[66]</xref><xref ref-type="bibr" rid="article-22958.r66">[67]</xref><xref ref-type="bibr" rid="article-22958.r67">[68]</xref><xref ref-type="bibr" rid="article-22958.r68">[69]</xref><xref ref-type="bibr" rid="article-22958.r69">[70]</xref><xref ref-type="bibr" rid="article-22958.r70">[71]</xref>&#x000a0;Timely recognition and proper management of these potential long-term complications among survivors of lymphoma are crucial to mitigate treatment-related morbidity and mortality.</p>
      </sec>
      <sec id="article-22958.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Being diagnosed with lymphocyte-depleted classic Hodgkin lymphoma and undergoing treatment can have significant psychosocial impacts on patients and their families. These can bring dramatic changes in their physical, spiritual, emotional, and interpersonal dimensions. Every clinic visit should include screening and assessing the emotional and social concerns of patients and their families. They should also be well-informed of the types of treatment, such as combined modality therapy versus chemotherapy alone, pros and cons of each treatment, side effects, supportive measures, regular follow-up, and long-term management plan.</p>
        <p>Furthermore, as some chemotherapeutic agents are known to affect fertility, patients should be counseled for options&#x000a0;such as sperm banking and egg freezing to preserve fertility. Regular follow-up with primary care physicians and oncologists is also important to monitor treatment response and treatment-related toxicities such as cardiotoxicity and pulmonary toxicity.</p>
      </sec>
      <sec id="article-22958.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A patient-centered teamwork approach is of vital importance when managing patients with lymphocyte-depleted classic Hodgkin lymphoma. An interprofessional team comprising of primary care physicians, oncologists, nursing staff, radiologists, palliative services, social workers, and case managers should work together in every step of treatment to provide comprehensive care for patients and their families, in prevention and management of complications, regular follow-up, survivorship care, psychosocial support, and in end-of-life care.</p>
      </sec>
      <sec id="article-22958.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22958&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22958">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/lymphocyte-depleted-hodgkin-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22958">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22958/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22958">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22958.s16">
        <title>References</title>
        <ref id="article-22958.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimabukuro-Vornhagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haverkamp</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balleisen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Majunke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heil</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Josting</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Aug</month>
            <day>20</day>
            <volume>23</volume>
            <issue>24</issue>
            <fpage>5739</fpage>
            <page-range>5739-45</page-range>
            <pub-id pub-id-type="pmid">16009944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allemani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marcos-Gragera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coebergh</surname>
                <given-names>JW</given-names>
              </name>
              <collab>EUROCARE Working Group</collab>
            </person-group>
            <article-title>Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups.</article-title>
            <source>Cancer</source>
            <year>2006</year>
            <month>Jul</month>
            <day>15</day>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-60</page-range>
            <pub-id pub-id-type="pmid">16770772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Irfan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Parveen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinico-Hematological Findings for Classical Hodgkin's Lymphoma: an Institutional Experience.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2016</year>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>4009</fpage>
            <page-range>4009-11</page-range>
            <pub-id pub-id-type="pmid">27644653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kant</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>DeVita</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease.</article-title>
            <source>J Clin Oncol</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-94</page-range>
            <pub-id pub-id-type="pmid">3754003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klimm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eichenauer</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Haverkamp</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Oct</month>
            <day>10</day>
            <volume>29</volume>
            <issue>29</issue>
            <fpage>3914</fpage>
            <page-range>3914-20</page-range>
            <pub-id pub-id-type="pmid">21911729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karube</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.</article-title>
            <source>Pathol Res Pract</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>209</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-7</page-range>
            <pub-id pub-id-type="pmid">23478005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzankov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zimpfer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pehrs</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lugli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Went</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dirnhofer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.</article-title>
            <source>Mod Pathol</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1141</fpage>
            <page-range>1141-7</page-range>
            <pub-id pub-id-type="pmid">14614054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiels</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Koritzinsky</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Suneja</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>274</fpage>
            <page-range>274-81</page-range>
            <pub-id pub-id-type="pmid">24326629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Major</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kamdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabinovitch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2019</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1234</fpage>
            <page-range>1234-1243</page-range>
            <pub-id pub-id-type="pmid">30501432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roemer</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ligon</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Redd</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Homer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Daadi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Armand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chapuy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Rodig</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Aug</month>
            <day>10</day>
            <volume>34</volume>
            <issue>23</issue>
            <fpage>2690</fpage>
            <page-range>2690-7</page-range>
            <pub-id pub-id-type="pmid">27069084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marafioti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foss</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Laumen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Korbjuhn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lammert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Demel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Theil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>Feb</month>
            <day>15</day>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>1443</fpage>
            <page-range>1443-50</page-range>
            <pub-id pub-id-type="pmid">10666223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keir</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Butte</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>PD-1 and its ligands in tolerance and immunity.</article-title>
            <source>Annu Rev Immunol</source>
            <year>2008</year>
            <volume>26</volume>
            <fpage>677</fpage>
            <page-range>677-704</page-range>
            <pub-id pub-id-type="pmid">18173375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.</article-title>
            <source>Semin Oncol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>430</fpage>
            <page-range>430-9</page-range>
            <pub-id pub-id-type="pmid">21074057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lemke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krappmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mathas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zenke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scheidereit</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.</article-title>
            <source>J Exp Med</source>
            <year>2002</year>
            <month>Sep</month>
            <day>02</day>
            <volume>196</volume>
            <issue>5</issue>
            <fpage>605</fpage>
            <page-range>605-17</page-range>
            <pub-id pub-id-type="pmid">12208876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hinz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krappmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lietz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jundt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bommert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mechta-Grigoriou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scheidereit</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.</article-title>
            <source>EMBO J</source>
            <year>2002</year>
            <month>Aug</month>
            <day>01</day>
            <volume>21</volume>
            <issue>15</issue>
            <fpage>4104</fpage>
            <page-range>4104-13</page-range>
            <pub-id pub-id-type="pmid">12145210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weniger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Melzner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Menz</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Wegener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bucur</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Dorsch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mattfeldt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.</article-title>
            <source>Oncogene</source>
            <year>2006</year>
            <month>Apr</month>
            <day>27</day>
            <volume>25</volume>
            <issue>18</issue>
            <fpage>2679</fpage>
            <page-range>2679-84</page-range>
            <pub-id pub-id-type="pmid">16532038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juszczynski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.</article-title>
            <source>Clin Cancer Res</source>
            <year>2012</year>
            <month>Mar</month>
            <day>15</day>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>1611</fpage>
            <page-range>1611-8</page-range>
            <pub-id pub-id-type="pmid">22271878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kube</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holtick</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Vockerodt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmadi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Behrmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tesch</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>STAT3 is constitutively activated in Hodgkin cell lines.</article-title>
            <source>Blood</source>
            <year>2001</year>
            <month>Aug</month>
            <day>01</day>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>762</fpage>
            <page-range>762-70</page-range>
            <pub-id pub-id-type="pmid">11468177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guasparri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bubman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cesarman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Apr</month>
            <day>01</day>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>3813</fpage>
            <page-range>3813-20</page-range>
            <pub-id pub-id-type="pmid">18230756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.</article-title>
            <source>J Pathol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>205</volume>
            <issue>4</issue>
            <fpage>498</fpage>
            <page-range>498-506</page-range>
            <pub-id pub-id-type="pmid">15714459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugden</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>CD40 and its viral mimic, LMP1: similar means to different ends.</article-title>
            <source>Cell Signal</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-16</page-range>
            <pub-id pub-id-type="pmid">12401515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grewal</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Flavell</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The role of CD40 ligand in costimulation and T-cell activation.</article-title>
            <source>Immunol Rev</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>153</volume>
            <fpage>85</fpage>
            <page-range>85-106</page-range>
            <pub-id pub-id-type="pmid">9010720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f6;mig-H&#x000f6;lzel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seagal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rajewsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zimber-Strobl</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Feb</month>
            <day>01</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>1448</fpage>
            <page-range>1448-55</page-range>
            <pub-id pub-id-type="pmid">18006702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imbeault</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouellet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gigu&#x000e8;re</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bertin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000e9;langer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tremblay</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment.</article-title>
            <source>J Virol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>2189</fpage>
            <page-range>2189-200</page-range>
            <pub-id pub-id-type="pmid">21177803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curreli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lunardi-Iskandar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lafferty</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Garzino-Demo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zella</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>B cell lymphoma in HIV transgenic mice.</article-title>
            <source>Retrovirology</source>
            <year>2013</year>
            <month>Aug</month>
            <day>28</day>
            <volume>10</volume>
            <fpage>92</fpage>
            <pub-id pub-id-type="pmid">23985023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vendrame</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Breen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Magpantay</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Widney</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Variakojis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knowlton</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bream</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ambinder</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Detels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Maza</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>343</fpage>
            <page-range>343-9</page-range>
            <pub-id pub-id-type="pmid">24220912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martorelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mastorci</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dal Col</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fa&#x000e8;</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giagulli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caccuri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rusnati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiorentini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dolcetti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.</article-title>
            <source>Int J Cancer</source>
            <year>2015</year>
            <month>Sep</month>
            <day>15</day>
            <volume>137</volume>
            <issue>6</issue>
            <fpage>1374</fpage>
            <page-range>1374-85</page-range>
            <pub-id pub-id-type="pmid">25704763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slack</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sohani</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Longtine</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Zukerberg</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>937</fpage>
            <page-range>937-43</page-range>
            <pub-id pub-id-type="pmid">19455461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lengfelder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
              <collab>German Low-grade Lymphoma Study Group (GLSG)</collab>
            </person-group>
            <article-title>Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel.</article-title>
            <source>Ann Hematol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>8</issue>
            <fpage>1281</fpage>
            <page-range>1281-6</page-range>
            <pub-id pub-id-type="pmid">27236576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hehn</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Utility of fine-needle aspiration as a diagnostic technique in lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Aug</month>
            <day>01</day>
            <volume>22</volume>
            <issue>15</issue>
            <fpage>3046</fpage>
            <page-range>3046-52</page-range>
            <pub-id pub-id-type="pmid">15284254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraway</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Strategies to diagnose lymphoproliferative disorders by fine-needle aspiration by using ancillary studies.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Dec</month>
            <day>25</day>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>432</fpage>
            <page-range>432-42</page-range>
            <pub-id pub-id-type="pmid">16222688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bednaruk-M&#x00142;y&#x00144;ski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pie&#x00144;kowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sk&#x000f3;rzak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ma&#x00142;kowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kulikowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Subocz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dzietczenia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zalewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le&#x0015b;niewski-Kmak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zaucha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wr&#x000f3;bel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zaucha</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>377</fpage>
            <page-range>377-82</page-range>
            <pub-id pub-id-type="pmid">24794802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Franceschetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fulham</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Almquist</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hjorthaug</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Viney</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luminari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trotman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Foss&#x000e5;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berkahn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Molin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D'Amore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Mar</month>
            <day>24</day>
            <volume>127</volume>
            <issue>12</issue>
            <fpage>1531</fpage>
            <page-range>1531-8</page-range>
            <pub-id pub-id-type="pmid">26747247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blodgett</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ames</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Torok</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>McCook</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin.</article-title>
            <source>Clin Nucl Med</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-3</page-range>
            <pub-id pub-id-type="pmid">15162984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>TA</given-names>
              </name>
              <collab>Alliance, Australasian Leukaemia and Lymphoma Group</collab>
              <collab>Eastern Cooperative Oncology Group</collab>
              <collab>European Mantle Cell Lymphoma Consortium</collab>
              <collab>Italian Lymphoma Foundation</collab>
              <collab>European Organisation for Research</collab>
              <collab>Treatment of Cancer/Dutch Hemato-Oncology Group</collab>
              <collab>Grupo Espa&#x000f1;ol de M&#x000e9;dula &#x000d3;sea</collab>
              <collab>German High-Grade Lymphoma Study Group</collab>
              <collab>German Hodgkin's Study Group</collab>
              <collab>Japanese Lymphorra Study Group</collab>
              <collab>Lymphoma Study Association</collab>
              <collab>NCIC Clinical Trials Group</collab>
              <collab>Nordic Lymphoma Study Group</collab>
              <collab>Southwest Oncology Group</collab>
              <collab>United Kingdom National Cancer Research Institute</collab>
            </person-group>
            <article-title>Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>20</day>
            <volume>32</volume>
            <issue>27</issue>
            <fpage>3059</fpage>
            <page-range>3059-68</page-range>
            <pub-id pub-id-type="pmid">25113753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanbhag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ambinder</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Hodgkin lymphoma: A review and update on recent progress.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-132</page-range>
            <pub-id pub-id-type="pmid">29194581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Ambinder</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Benitez</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bernat</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Hernandez-Ilizaliturri</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Kaminski</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kenkre</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Mauch</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mulroney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poppe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabinovitch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seropian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ogba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>608</fpage>
            <page-range>608-638</page-range>
            <pub-id pub-id-type="pmid">28476741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tubiana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henry-Amar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burgers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sizoo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Van der Schueren</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease.</article-title>
            <source>Cancer</source>
            <year>1984</year>
            <month>Sep</month>
            <day>01</day>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>885</fpage>
            <page-range>885-94</page-range>
            <pub-id pub-id-type="pmid">6378359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry-Amar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meerwaldt</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Carde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burgers</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Monconduit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noordijk</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group.</article-title>
            <source>Ann Intern Med</source>
            <year>1991</year>
            <month>Mar</month>
            <day>01</day>
            <volume>114</volume>
            <issue>5</issue>
            <fpage>361</fpage>
            <page-range>361-5</page-range>
            <pub-id pub-id-type="pmid">1992877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moccia</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chhanabhai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoskins</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Klasa</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Shenkier</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Slack</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Skinnider</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Sep</month>
            <day>20</day>
            <volume>30</volume>
            <issue>27</issue>
            <fpage>3383</fpage>
            <page-range>3383-8</page-range>
            <pub-id pub-id-type="pmid">22869887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papakonstantinou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kosmidou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papathanasiou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koumpis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kapsali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Milionis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vassilakopoulos</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Papoudou-Bai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hatzimichael</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.</article-title>
            <source>In Vivo</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>1951</fpage>
            <page-range>1951-1957</page-range>
            <pub-id pub-id-type="pmid">34182468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pl&#x000fc;tschow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Lohri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Willborn</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Debus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eble</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>S&#x000f6;kler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ganser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;mper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirchner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kr&#x000e1;l</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Hermelink</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Aug</month>
            <day>12</day>
            <volume>363</volume>
            <issue>7</issue>
            <fpage>640</fpage>
            <page-range>640-52</page-range>
            <pub-id pub-id-type="pmid">20818855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rgen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Markova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Debus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grosu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wiegel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karstens</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Willich</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schmidberger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Hermelink</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>20</day>
            <volume>28</volume>
            <issue>27</issue>
            <fpage>4199</fpage>
            <page-range>4199-206</page-range>
            <pub-id pub-id-type="pmid">20713848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Counsell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pettengell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wimperis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Culligan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Popova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brownell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kruger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoskin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Apr</month>
            <day>23</day>
            <volume>372</volume>
            <issue>17</issue>
            <fpage>1598</fpage>
            <page-range>1598-607</page-range>
            <pub-id pub-id-type="pmid">25901426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>MPE</given-names>
              </name>
              <name>
                <surname>Girinsky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fortpied</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casasnovas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Maazen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edeline</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ferm&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Imhoff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sebban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stamatoullas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delarue</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fiaccadori</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bellei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raveloarivahy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Versari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meignan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raemaekers</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>35</volume>
            <issue>16</issue>
            <fpage>1786</fpage>
            <page-range>1786-1794</page-range>
            <pub-id pub-id-type="pmid">28291393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;ll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goergen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Behringer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;ckelmann</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hitz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kerkhoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eichenauer</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rkle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>05</day>
            <volume>127</volume>
            <issue>18</issue>
            <fpage>2189</fpage>
            <page-range>2189-92</page-range>
            <pub-id pub-id-type="pmid">26834240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skoetz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monsef</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brillant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD007941</fpage>
            <pub-id pub-id-type="pmid">28541603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goergen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lohri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichenauer</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Zijlstra</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Markova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feuring-Buske</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000fc;ttmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dierlamm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soekler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Willenbacher</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Topp</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hitz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hnhardt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ostermann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aulitzky</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maschmeyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vieler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baues</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuhnert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dietlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Dec</month>
            <day>23</day>
            <volume>390</volume>
            <issue>10114</issue>
            <fpage>2790</fpage>
            <page-range>2790-2802</page-range>
            <pub-id pub-id-type="pmid">29061295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Gallamini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alekseev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ill&#x000e9;s</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Picardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lech-Maranda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smolewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Walewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramchandren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Josephson</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jolin</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Huebner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <collab>ECHELON-1 Study Group</collab>
            </person-group>
            <article-title>Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>25</day>
            <volume>378</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-344</page-range>
            <pub-id pub-id-type="pmid">29224502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cerci</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pracchia</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Linardi</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Pitella</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Delbeke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Izaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buccheri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meneghetti</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.</article-title>
            <source>J Nucl Med</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>9</issue>
            <fpage>1337</fpage>
            <page-range>1337-43</page-range>
            <pub-id pub-id-type="pmid">20720036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Kostakoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meignan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;eller</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Trotman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hustinx</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biggi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>20</day>
            <volume>32</volume>
            <issue>27</issue>
            <fpage>3048</fpage>
            <page-range>3048-58</page-range>
            <pub-id pub-id-type="pmid">25113771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foss&#x000e5;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berkahn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>d'Amore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Enblad</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franceschetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fulham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luminari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sidra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trotman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viney</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Jun</month>
            <day>23</day>
            <volume>374</volume>
            <issue>25</issue>
            <fpage>2419</fpage>
            <page-range>2419-29</page-range>
            <pub-id pub-id-type="pmid">27332902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taparra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Polley</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ristow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-308</page-range>
            <pub-id pub-id-type="pmid">31517559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaucha</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chauvie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaucha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biggii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallamini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of PET/CT in the modern treatment of Hodgkin lymphoma.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>77</volume>
            <fpage>44</fpage>
            <page-range>44-56</page-range>
            <pub-id pub-id-type="pmid">31260900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nowakowski</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Micallef</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Inwards</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Botto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ristow</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?</article-title>
            <source>Leuk Lymphoma</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-327</page-range>
            <pub-id pub-id-type="pmid">31556355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linch</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Winfield</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldstone</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Moir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Milligan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Apr</month>
            <day>24</day>
            <volume>341</volume>
            <issue>8852</issue>
            <fpage>1051</fpage>
            <page-range>1051-4</page-range>
            <pub-id pub-id-type="pmid">8096958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pfistner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sextro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sieber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Haenel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boissevain</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zschaber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirchner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lohri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hasenclever</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldstone</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <collab>German Hodgkin's Lymphoma Study Group</collab>
              <collab>Lymphoma Working Party of the European Group for Blood and Marrow Transplantation</collab>
            </person-group>
            <article-title>Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Jun</month>
            <day>15</day>
            <volume>359</volume>
            <issue>9323</issue>
            <fpage>2065</fpage>
            <page-range>2065-71</page-range>
            <pub-id pub-id-type="pmid">12086759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Nademanee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masszi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Agura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Holowiecki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abidi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Stiff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osmanov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bachanova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sweetenham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huebner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sievers</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Walewski</surname>
                <given-names>J</given-names>
              </name>
              <collab>AETHERA Study Group</collab>
            </person-group>
            <article-title>Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>May</month>
            <day>09</day>
            <volume>385</volume>
            <issue>9980</issue>
            <fpage>1853</fpage>
            <page-range>1853-62</page-range>
            <pub-id pub-id-type="pmid">25796459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaloyannidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schrover</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nikoglou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.</article-title>
            <source>Br J Haematol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>188</volume>
            <issue>4</issue>
            <fpage>540</fpage>
            <page-range>540-549</page-range>
            <pub-id pub-id-type="pmid">31588564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Timmerman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Ramchandren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>De Boer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Trneny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sumbul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farsaci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>36</volume>
            <issue>14</issue>
            <fpage>1428</fpage>
            <page-range>1428-1439</page-range>
            <pub-id pub-id-type="pmid">29584546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Armand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Brice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribrag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vassilakopoulos</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nahar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balakumaran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Oct</month>
            <day>03</day>
            <volume>134</volume>
            <issue>14</issue>
            <fpage>1144</fpage>
            <page-range>1144-1153</page-range>
            <pub-id pub-id-type="pmid">31409671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canals</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Boogaerts</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornelissen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gramatzki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niederwieser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Jan</month>
            <day>20</day>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>455</fpage>
            <page-range>455-62</page-range>
            <pub-id pub-id-type="pmid">18086796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaudio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palazzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pisapia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carluccio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cascavilla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Specchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pavone</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40</page-range>
            <pub-id pub-id-type="pmid">30293754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertoglio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lomangino</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Querzoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonalumi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bogina</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Terzi</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Primary Hodgkin lymphoma of the lung arising with hemoptysis and pulmonary consolidation: a case report.</article-title>
            <source>Monaldi Arch Chest Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <day>10</day>
            <volume>91</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34121376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoskin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rohatiner</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Linch</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Nov</month>
            <day>01</day>
            <volume>29</volume>
            <issue>31</issue>
            <fpage>4096</fpage>
            <page-range>4096-104</page-range>
            <pub-id pub-id-type="pmid">21969511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franklin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pluetschow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anselmo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Aviles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bogatyreva</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bonadonna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brillant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cavalieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eghbali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ferm&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Henry-Amar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Niedzwiecki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pavlovsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raemaekers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shakhtarina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valagussa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilimas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.</article-title>
            <source>Ann Oncol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1749</fpage>
            <page-range>1749-60</page-range>
            <pub-id pub-id-type="pmid">16984979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aleman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>van den Belt-Dusebout</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>De Bruin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>van 't Veer</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Baaijens</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Klokman</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kuenen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ouwens</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bartelink</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Late cardiotoxicity after treatment for Hodgkin lymphoma.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Mar</month>
            <day>01</day>
            <volume>109</volume>
            <issue>5</issue>
            <fpage>1878</fpage>
            <page-range>1878-86</page-range>
            <pub-id pub-id-type="pmid">17119114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mauch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dinshaw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loeffler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy.</article-title>
            <source>Eur J Haematol Suppl</source>
            <year>2005</year>
            <month>Jul</month>
            <issue>66</issue>
            <fpage>68</fpage>
            <page-range>68-76</page-range>
            <pub-id pub-id-type="pmid">16007872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behringer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Breuer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reineke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nogova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klimm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wildt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Engert</surname>
                <given-names>A</given-names>
              </name>
              <collab>German Hodgkin's Lymphoma Study Group</collab>
            </person-group>
            <article-title>Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Oct</month>
            <day>20</day>
            <volume>23</volume>
            <issue>30</issue>
            <fpage>7555</fpage>
            <page-range>7555-64</page-range>
            <pub-id pub-id-type="pmid">16234521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22958.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Kaaij</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Heutte</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Stang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Raemaekers</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Carde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Noordijk</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ferm&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eghbali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Henry-Amar</surname>
                <given-names>M</given-names>
              </name>
              <collab>European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group</collab>
              <collab>Groupe d'Etude des Lymphomes de l'Adulte</collab>
            </person-group>
            <article-title>Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>19</issue>
            <fpage>2825</fpage>
            <page-range>2825-32</page-range>
            <pub-id pub-id-type="pmid">17515571</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
